Purchase this article with an account.
Rocio I Diaz, Eric J Sigler, Mohammad Rafieetary, Jorge I Calzada; Ocular Histoplasmosis Syndrome: morphology and clinical spectrum. Invest. Ophthalmol. Vis. Sci. 2014;55(13):672.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the clinical, imaging, and treatment characteristics of patients with ocular histoplasmosis syndrome (OHS)
Retrospective, longitudinal study evaluating consecutive patients with OHS. Clinical and imaging characteristics were analyzed. Chorioretinal lesions were further analyzed with SD-OCT in all patients within the study period.
313 eyes of 157 patients were diagnosed with OHS. Mean age was 51.7±17.7 years. 67% of patients had a follow-up equal or greater than 6 months. 41% of eyes had an active choroidal neovascularization (CNV) on SD-OCT. 14% of eyes had disciform scars at presentation. 67% had type II CNV. CNV types were not associated with worse initial (p=0.162) or final (p=0.151) BCVA. The presence of macular OHS lesions was not associated with the presence of active CNV(p=0.583). 112/169 treated eyes (66%) received anti VEGF therapy. Mean final BCVA was significantly better than initial BCVA among eyes that received anti VEGF therapy (p<0.001)
Up to 55% of eyes developed some type of CNV or associated sequelae. OHS CNVs may present as any type of CNV, but are predominantly type II. Location of the CNV plays a more important role in final BCVA than type of CNV. Anti VEGF treatment is a viable option for subfoveal and juxtafoveal CNVs, similar to previous reports
This PDF is available to Subscribers Only